Trials / Completed
CompletedNCT04956783
Occurrence of Adverse Effects With Immune Checkpoint Inhibitors Between a Single and Double Dose Regimen
Comparison of the Occurrence of Adverse Effects With Immune Checkpoint Inhibitors Between a Single and Double Dose Regimen
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective evaluation of the impact of a double dose regimen of immunotherapy use in cancer treatment compared to the single-dose regimen on the occurrence of clinically significant adverse events. The aim of this study is to provide evidence-based arguments to help clinicians to propose the best treatment regimen for each patient.
Conditions
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
- First posted
- 2021-07-09
- Last updated
- 2021-07-20
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04956783. Inclusion in this directory is not an endorsement.